Laurus Labs

Why is Laurus Labs Ltd falling/rising?

As of 10-Aug, Laurus Labs Ltd's stock price is rising, currently at 1,866.00, reflecting a strong performance with a 21.31% increase over the past month and a 127.26% rise over the last year, significantly outperforming the Sensex. Positive factors include high institutional holdings, consistent profit growth, and trading above moving averages, contributing to a favorable outlook despite some long-term growth concerns.

As of 10-Aug, Laurus Labs Ltd's stock price is rising, currently at 1,866.00, reflecting an increase of 11.0 (0.59%). This upward movement can be attributed to several positive factors. The stock has shown strong performance over various periods, with a notable 21.31% increase over the past month and a remarkable 127.26% rise over the last year, significantly outperforming the Sensex, which has seen a decline of 1.65% in the same timeframe.<BR><BR>Today, the stock reached a new 52-week high of Rs. 1870 and has been gaining for the last two days, with a total return of 1.63% during this period. Additionally, Laurus Labs is trading above its moving averages across multiple time frames, indicating a strong bullish trend. The company's financial health is also a contributing factor, as it reported a substantial growth in net profit of 124.73% and has declared positive results for the last seven consecutive quarters.<BR><BR>Moreover, the stock has high institutional holdings at 41.74%, which suggests confidence from larger investors who typically have better resources to analyze the company's fundamentals. This institutional support, combined with the company's impressive operational metrics, such as a high return on capital employed (ROCE) of 15.19%, reinforces the positive sentiment surrounding the stock.<BR><BR>Despite some concerns regarding long-term growth rates in net sales and operating profit, the overall market-beating performance and strong recent results have led to a favorable outlook for Laurus Labs Ltd, contributing to its rising stock price.

Which are the latest news on Laurus Labs?

Are Laurus Labs Ltd latest results good or bad?

Laurus Labs Ltd's latest results are strong, with net sales increasing by 29.10% year-on-year to ₹2,026.31 crores and net profit rising by 125.49% to ₹367.60 crores, indicating a positive financial performance and growth in the pharmaceutical sector.

Laurus Labs Ltd's latest results are quite strong, reflecting a significant turnaround in their financial performance. For the quarter ending June 2026, the company reported net sales of ₹2,026.31 crores, which is a remarkable increase of 29.10% year-on-year and 11.85% quarter-on-quarter. This growth is particularly impressive as it marks the highest quarterly sales in the company's history.<BR><BR>The net profit for the same period reached ₹367.60 crores, representing a substantial year-on-year increase of 125.49%. Additionally, the operating profit margin expanded to 31.50%, the highest in recent quarters, showcasing effective cost management and operational leverage.<BR><BR>Overall, Laurus Labs has demonstrated strong revenue growth, significant profit expansion, and improved margins, indicating a positive trajectory for the company. These results suggest that Laurus Labs is performing well and is positioned favorably within the pharmaceutical sector.

Should I buy, sell or hold Laurus Labs Ltd?

When is the next results date for Laurus Labs Ltd?

The next results date for Laurus Labs Ltd is July 24, 2026.

The next results date for Laurus Labs Ltd is scheduled for July 24, 2026.

What does Laurus Labs do?

Laurus Labs Ltd is a mid-cap pharmaceutical and biotechnology company specializing in generic active pharmaceutical ingredients (APIs). As of March 2026, it reported net sales of ₹1,812 Cr and a net profit of ₹279 Cr, with a market cap of ₹76,073 Cr.

Overview: <BR>Laurus Labs Ltd is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company operating in the mid-cap segment of the Pharmaceuticals & Biotechnology industry, specializing in generic active pharmaceutical ingredients (APIs) across various therapeutic areas.<BR><BR>History: <BR>Laurus Labs was incorporated in an unspecified year and has maintained its status as a leading manufacturer in its field. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,812 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 279 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 76,073 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 84.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.14% <BR>Debt-Equity: 0.45 <BR>Return on Equity: 16.77% <BR>Price to Book: 14.50 <BR><BR>Contact Details: <BR>Address: Plot No 21 Jawaharlal Nehru, Pharma City Parawada Visakhapatnam Andhra Pradesh : 531021 <BR>Tel: 91-891-3061222 <BR>Email: secretarial@lauruslabs.com <BR>Website: http://www.lauruslabs.com

How big is Laurus Labs?

As of 10th June, Laurus Labs Ltd has a market capitalization of 76,073.00 Cr, with net sales of 6,812.90 Cr and a net profit of 888.79 Cr reported in the latest four quarters.

As of 10th June, Laurus Labs Ltd has a market capitalization of 76,073.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Laurus Labs reported net sales of 6,812.90 Cr and a net profit of 888.79 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 4,472.56 Cr and total assets of 9,335.57 Cr.

Who are in the management team of Laurus Labs?

The management team of Laurus Labs includes M V G Rao (Chairman), Chava Satyanarayana (CEO), Venkata Ravi Kumar Vantaram (CFO), and several independent directors: Aruna Bhinge, Rajesh Koshy Chandy, and Ravindranath Kancherla, along with Executive Director Venkata Lakshmana Rao Chunduru. They are responsible for the company's strategic direction and operations.

The management team of Laurus Labs includes the following key members:<BR><BR>1. **M V G Rao** - Chairman & Independent Director<BR>2. **Chava Satyanarayana** - Executive Director & CEO<BR>3. **Venkata Ravi Kumar Vantaram** - Executive Director & CFO<BR>4. **Aruna Bhinge** - Independent Non-Executive Director<BR>5. **Rajesh Koshy Chandy** - Independent Non-Executive Director<BR>6. **Ravindranath Kancherla** - Independent Non-Executive Director<BR>7. **Venkata Lakshmana Rao Chunduru** - Executive Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Laurus Labs?

Laurus Labs' peers include Cipla, Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Biocon, Alkem Lab, Glenmark Pharma, Abbott India, and Anthem Bioscienc. Laurus Labs has the highest 1-year return at 106.68%, while Abbott India has the lowest at -16.68%.

Peers: The peers of Laurus Labs are Cipla, Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Biocon, Alkem Lab, Glenmark Pharma, Abbott India, and Anthem Bioscienc.<BR><BR>Quality Snapshot: Excellent management risk is observed at Cipla, Dr Reddy's Labs, Lupin, Mankind Pharma, Alkem Lab, Glenmark Pharma, and Anthem Bioscienc, while Average management risk is found at Aurobindo Pharma and Biocon. Good growth is seen at Dr Reddy's Labs, Lupin, Mankind Pharma, and Glenmark Pharma, while Below Average growth is noted for Cipla, Aurobindo Pharma, Laurus Labs, Biocon, and Alkem Lab. Excellent capital structure is present at Cipla, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, Alkem Lab, and Abbott India, while Average capital structure is found at Laurus Labs and Good capital structure at Lupin and Glenmark Pharma, and Below Average capital structure is observed at Biocon.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 106.68%, while Abbott India has the lowest at -16.68%, indicating Laurus Labs significantly outperforms Abbott India. Additionally, peers such as Alkem Lab and Abbott India have negative six-month returns.

Is Laurus Labs overvalued or undervalued?

As of October 28, 2025, Laurus Labs is considered very expensive and overvalued with a PE ratio of 75.74, significantly higher than its peers, despite outperforming the Sensex with a year-to-date return of 59.32%.

As of 28 October 2025, the valuation grade for Laurus Labs has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued, with a PE ratio of 75.74, an EV to EBITDA of 45.57, and a PEG ratio of 0.18, which suggests that despite high earnings multiples, the growth expectations are not sufficiently justified by its financial performance.<BR><BR>In comparison to its peers, Laurus Labs stands out with a notably higher PE ratio than Sun Pharma Industries at 35.35 and Divi's Laboratories at 74.05, both of which are categorized as expensive or very expensive. Additionally, while Laurus Labs has a lower EV to EBITDA than Divi's, it still remains significantly above the industry average, reinforcing its overvaluation status. Notably, Laurus Labs has outperformed the Sensex in recent periods, with a year-to-date return of 59.32% compared to the Sensex's 8.30%, which may contribute to inflated expectations surrounding its valuation.

How has been the historical performance of Laurus Labs?

Laurus Labs has shown fluctuating financial performance, with net sales increasing from 4,813.51 crore in March 2021 to 5,553.96 crore in March 2025, while profitability metrics like profit after tax declined from 983.82 crore to 354.41 crore in the same period. Despite significant growth in sales and total assets, the company has faced volatility in profitability and cash flow challenges.

Answer:<BR>The historical performance of Laurus Labs shows a fluctuating trend in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Laurus Labs' net sales increased from 4,813.51 crore in March 2021 to 5,553.96 crore in March 2025, despite a dip to 4,935.57 crore in March 2022 and a peak of 6,040.55 crore in March 2023. Total operating income followed a similar pattern, reaching 5,553.96 crore in March 2025. The company's total expenditure, excluding depreciation, rose from 2,267.17 crore in March 2020 to 4,498.68 crore in March 2025, reflecting increased operational costs. Operating profit (PBDIT) peaked at 1,598.19 crore in March 2023 but fell to 1,130.38 crore by March 2025. Profit before tax also saw fluctuations, peaking at 1,301.11 crore in March 2021 before declining to 484.29 crore in March 2025. Profit after tax followed a similar trend, with a high of 983.82 crore in March 2021 and a decrease to 354.41 crore in March 2025. The company's total assets grew from 3,676.39 crore in March 2020 to 9,335.57 crore in March 2025, while total liabilities increased from 1,935.94 crore to 2,693.08 crore in the same period. Cash flow from operating activities showed a decline from 993 crore in March 2023 to 601 crore in March 2025, indicating challenges in cash generation despite revenue growth. Overall, Laurus Labs has experienced significant growth in sales and assets, but profitability has faced volatility in recent years.

Is Laurus Labs technically bullish or bearish?

As of 20 October 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly indicators show mild bearishness and mixed signals from RSI readings.

As of 20 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum, while the weekly MACD and KST are mildly bearish, suggesting some caution. The monthly MACD remains bullish, and Bollinger Bands are bullish across both weekly and monthly time frames. However, the weekly RSI shows no signal and the monthly RSI is bearish, indicating mixed signals. Overall, the strength of the bullish stance is tempered by the mildly bearish indicators on the weekly charts.

Who are the top shareholders of the Laurus Labs?

The top shareholders of Laurus Labs include M/s. Nsn Holdings (23.02%), foreign institutional investors (25.52%), mutual funds (6.88%), individual investors (23.65%), and New World Fund Inc (6.5%), with a pledged promoter holding of 2.6853%.

The top shareholders of Laurus Labs include a mix of institutional and individual investors. The largest shareholder is M/s. Nsn Holdings, represented by Dr. Satyanarayana Chava, holding 23.02%. Following that, foreign institutional investors (FIIs) collectively hold 25.52%, while mutual funds account for 6.88% through 29 different schemes. Individual investors own 23.65% of the company, and the highest public shareholder is New World Fund Inc, with a stake of 6.5%. Additionally, there is a pledged promoter holding of 2.6853%.

Has Laurus Labs declared dividend?

Laurus Labs has declared a 40% dividend, amounting to ₹0.8 per share, with an ex-date of May 9, 2025. The company has shown strong total returns over various periods, notably a 581.02% total return over the last 5 years.

Laurus Labs Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: 0.8<BR>- Ex-date: May-09-2025<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>Over the 6-month period, Laurus Labs experienced a price return of 7.42%, a dividend return of 0.14%, resulting in a total return of 7.56%.<BR><BR>In the 1-year period, the company saw a price return of 48.13%, a dividend return of 0.27%, leading to a total return of 48.4%.<BR><BR>For the 2-year period, Laurus Labs reported a price return of 85.48%, with a dividend return of 0.55%, culminating in a total return of 86.03%.<BR><BR>During the 3-year period, the price return was 15.04%, the dividend return was 0.89%, resulting in a total return of 15.93%.<BR><BR>In the 4-year period, the company achieved a price return of 16.03%, a dividend return of 0.89%, which led to a total return of 16.92%.<BR><BR>Over the 5-year period, Laurus Labs recorded a remarkable price return of 573.41%, with a dividend return of 7.61%, resulting in an impressive total return of 581.02%.<BR><BR>Overall, Laurus Labs has declared a substantial dividend, and the total returns over various periods indicate strong performance, particularly in the long term, highlighting the company's growth and shareholder value.